

## (Neo-)Adjuvant Chemotherapy Algorithm in Early Stage Invasive Breast Cancer

**\*\*\*Consider entry into clinical trials for all eligible patients\*\*\***

	ER +ve	HER2+ve	TNBC	BRCA +ve TNBC
<b>Neo-adjuvant</b>	<p>EC x 3 - Docetaxel<sub>100</sub> x 3</p> <p><i>or, if inflammatory breast cancer, consider</i></p> <p>Acc EC x 4, Acc Paclitaxel x 4</p> <p><i>or</i></p> <p>Consider neo-adjuvant endocrine therapy in appropriate patients</p>	<p>Accelerated EC x 3,</p> <p>followed by</p> <p>Docetaxel<sub>75</sub> x 4,</p> <p><b>Pertuzumab</b> and Trastuzumab</p> <p><i>(plus adjuvant trastuzumab post surgery, to total 18 doses)</i></p>	<p>Accelerated EC x 4,</p> <p>Acc Paclitaxel x 4</p> <p><i>or, for selected patients,</i></p> <p>Accelerated EC x 4,</p> <p>followed by</p> <p><b>Carboplatin (3 weekly) with Paclitaxel (weekly)</b></p> <p><i>(+/- followed by adjuvant capecitabine, if incomplete response)</i></p>	<p>Accelerated EC x 4,</p> <p>followed by</p> <p><b>Carboplatin (3 weekly) with Paclitaxel (weekly)</b></p> <p><i>(+/- followed by adjuvant capecitabine, if incomplete response)</i></p>
<b>Adjuvant</b>	EC x 3 - Docetaxel <sub>100</sub> x 3	EC x 3 - Docetaxel <sub>100</sub> x 3 plus S/C Herceptin x 18 doses	Accelerated EC x 4, Acc Paclitaxel x 4 <i>(+ addition of carboplatin, as above, in selected high risk pts)</i>	Accelerated EC x 4, Acc Paclitaxel x 4 <i>(+ addition of carboplatin, as above, in selected high risk pts)</i>
<b>Alternative options</b> <i>(if above not suitable)</i>	Docetaxel <sub>(75)</sub> + cyclophosphamide	TCH (+ <b>pertuzumab</b> if neo-adjuvant) <i>or, in the adjuvant setting only,</i> Docetaxel <sub>(75)</sub> -cyclophosphamide plus S/C Herceptin x 18 doses	EC x 3 - Docetaxel <sub>100</sub> x 3 or Docetaxel <sub>(75)</sub> + cyclophosphamide	EC x 3 - Docetaxel <sub>100</sub> x 3 or Docetaxel <sub>(75)</sub> + cyclophosphamide
<b>Adjuvant use in small node negative, Her2+ve</b>		Paclitaxel weekly x 12 plus S/C Herceptin x 18 doses		
<b>For patients <i>only</i> where “alternative options” above not suitable</b>	EC x 4 or Paclitaxel weekly x 12	EC x 4	EC x 4 or Paclitaxel weekly x 12	EC x 4 or Paclitaxel weekly x 12
<b>Plus, for post-menopausal women</b>	Adjuvant Zoledronic acid 6 monthly x 3 years	Adjuvant Zoledronic acid 6 monthly x 3 years	Adjuvant Zoledronic acid 6 monthly x 3 years	Adjuvant Zoledronic acid 6 monthly x 3 years

**Blueteq registration required**

Version: 6	Approved by Consultant Oncologist: Dr R Laing
Reason for update: addition of adj cape; review of options for TNBC; ER+ve inflammatory breast cancer mentioned; neo-adj endocrine for ER+ve	Approved by Consultant Oncologist: Dr T Crook
Prepared by: S Taylor	Date: 29.1.18